Mitsubishi Chemical Group (4188) Q4 2026 earnings summary

Executive summary

• FY 2025 core operating income declined 2% to ¥225.0 billion, with operating income plunging 79% to ¥30.1 billion and profit attributable to owners down 74% to ¥11.8 billion, mainly due to non-recurring items and asset impairments.

• Major structural reforms included withdrawal from coke and carbon materials, ethylene restructuring, dissolution of overseas MMA JVs, and voluntary retirement programs.

• Specialty Materials performed steadily, but MMA and Basic Materials & Polymers faced a sluggish environment and market deterioration.

• Management acknowledged exceptional circumstances and announced voluntary compensation reductions for top executives.

• The transfer of Mitsubishi Tanabe Pharma Corporation was completed, with its operations now classified as discontinued.

Financial highlights

• FY 2025 sales revenue was ¥3,704.0 billion, down 6% year-over-year; core operating income was ¥225.0 billion, down 2%; operating income was ¥30.1 billion.

• Net income attributable to owners was ¥11.8 billion, down 74% year-over-year.

• Special items totaled negative ¥194.9 billion, including restructuring provisions, impairment losses, and special retirement payments.

• Free cash flow increased to ¥560.8 billion, driven by asset sales, notably the MTPC transfer.

• Total assets were ¥5,876.6 billion, down ¥18.0 billion from the previous year; net D/E ratio improved to 0.83.

Outlook and guidance

• FY 2026 core operating income is forecast at ¥305.0 billion, with profit attributable to owners expected to rise to ¥127.0 billion.

• Sales revenue for FY 2027 is projected at ¥3,800.0 billion, with net income attributable to owners at ¥227.0 billion.

• Dividend forecast for FY 2026 is ¥32 per share, unchanged from FY 2025.

• Guidance does not include potential impacts from Middle East tensions, which could reduce core operating income by ¥18.0 billion if disruptions persist.